# CHiR Therapy for Elderly DLBCL Intolerant to Chemo

> **NCT06764017** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Ningbo University** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** CHiR-DEL

## Key facts

- **NCT ID:** NCT06764017
- **Lead sponsor:** First Affiliated Hospital of Ningbo University
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764017, "CHiR Therapy for Elderly DLBCL Intolerant to Chemo". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06764017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*